2-吡啶-2-基-5-(三氟甲基)苯胺 | 158461-46-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-吡啶-2-基-5-(三氟甲基)苯胺
• 英文名称: 2-(pyridin-2-yl)-5-(trifluoromethyl)aniline
• 英文别名: 2-pyridin-2-yl-5-(trifluoromethyl)aniline
• CAS: 158461-46-2
• 化学式: C₁₂H₉F₃N₂
• 分子量: 238.212
• InChiKey: QMBZKMJAVNHCEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  309.4±42.0 °C(Predicted)
• 密度：
  1.296±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-吡啶-2-基-5-(三氟甲基)苯胺 在 溶剂黄146 、 sodium nitrite 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 1-methyl-2-(2-azido-4-trifluoromethylphenyl)pyridinium triflate
  参考文献：
  名称：

  RhII2催化芳基叠氮化物合成α-、β-或δ-咔啉

  摘要：

  接近所有异构体：使用羧酸铑 (II) 催化剂可从邻位取代芳基叠氮化物中轻松获得一系列 α-、β- 和 δ-咔啉鎓离子（参见方案）。咔啉离子很容易被还原以提供色氨酸或去质子化以获取吡啶并吲哚。这种 [Rh II 2 ]-催化的 C  H 键胺化用于合成 (±)-horsfiline 和新隐碱。esp=α,α,α',α'-四甲基-1,3-苯二丙酸酯。

  DOI：

  10.1002/anie.201201788
• 作为产物：
  描述：

  2-溴-5-三氟甲苯苯胺 在 barium hydroxide octahydrate 、 palladium diacetate 、 三乙胺 、 2-(二环己基膦基)联苯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 5.0h， 生成 2-吡啶-2-基-5-(三氟甲基)苯胺
  参考文献：
  名称：

  RhII2催化芳基叠氮化物合成α-、β-或δ-咔啉

  摘要：

  接近所有异构体：使用羧酸铑 (II) 催化剂可从邻位取代芳基叠氮化物中轻松获得一系列 α-、β- 和 δ-咔啉鎓离子（参见方案）。咔啉离子很容易被还原以提供色氨酸或去质子化以获取吡啶并吲哚。这种 [Rh II 2 ]-催化的 C  H 键胺化用于合成 (±)-horsfiline 和新隐碱。esp=α,α,α',α'-四甲基-1,3-苯二丙酸酯。

  DOI：

  10.1002/anie.201201788

文献信息

• [EN] PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS<br/>[FR] ACIDES PHÉNYLSULFAMOYLBENZOÏQUES EN TANT QUE MODULATEURS D'ERAP1
  申请人：GREY WOLF THERAPEUTICS LTD

  公开号：WO2020225569A1

  公开（公告）日：2020-11-12

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally substituted by one ormore substituents selected from alkyl, cycloalkyl, halo, alkoxy, CN, haloalkyl and OH; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, C land alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl,Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl andhaloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl,SO2NR12R13, heteroaryl, CONR10R11 and alkyl, wherein said heteroaryl group is optionallysubstituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl and halo; and R9 is H, alkyl or halo; R10 and R11 are each independently H or alkyl; and R12 and R13 are each independently H or alkyl. Further aspects of the invention relate to such compounds for use in the field of immuno- oncology and related applications. Another aspect of the invention relates to compounds of formulae (la) and (lb).

  本发明涉及一种具有式(I)的化合物，或其药学上可接受的盐或水合物，其中：基团X-Y为-NHSO2-或-SO2NH-；Z为单环芳基或杂环芳基，每个基团可选择地由一种或多种从烷基、环烷基、卤素、烷氧基、CN、卤代烷基和羟基中选择的取代基取代；R1为H或烷基；R2从COOH和四唑基团中选择；R3从H、C和烷基中选择；R4从H和卤素中选择；R5从H、烷基、卤代烷基、SO2-烷基、Cl、烷氧基、OH、CN、羟基烷基、烷基硫、杂环芳基、环烷基、杂环烷基和卤代烷氧基中选择；R6为H；R7从H、CN、卤代烷基、卤素、SO2-烷基、SO2NR12R13、杂环芳基、CONR10R11和烷基中选择，其中所述的杂环芳基可选择地由一种或多种从烷基、卤素、烷氧基、CN、卤代烷基和羟基中选择的取代基取代；R8从H、烷基、卤代烷基和卤素中选择；R9为H、烷基或卤素；R10和R11各自独立地为H或烷基；R12和R13各自独立地为H或烷基。本发明的进一步方面涉及这些化合物在免疫肿瘤学领域及相关应用中的用途。本发明的另一个方面涉及式(la)和(lb)的化合物。
• Synthesis and Antiarrhythmic Activity of Disubstituted Phenylpyridine Derivative.
  作者：Hiromichi SHIGYO、Seiichi SATO、Kimiyuki SHIBUYA、Yoshio TAKAHASHI、Takashi YAMAGUCHI、Hiroyuki SONOKI、Tomio OHTA

  DOI：10.1248/cpb.41.1573

  日期：——

  disubstituted phenylpyridine derivatives was synthesized and their antiarrhythmic effects against chloroform-induced ventricular arrhythmias in mice were examined. Among them, 2- and 3-[2-(3-aminobutyramido)-4-(2,2,2-trifluroethoxy)phenyl]pyri dines (23h, 24h) and 3-[2-(3-aminobutyramido)-4-ethoxyphenyl]pyridine (24i) showed potent antiarrhythmic activity. They had approximately twice the potency of mexiletine

  合成了一系列双取代的苯基吡啶衍生物，并研究了它们对氯仿诱导的小鼠心律失常的抗心律失常作用。其中，2-和3- [2-（3-氨基丁酰胺基）-4-（2,2,2-三氟乙氧基）苯基]嘧啶二烯（23h，24h）和3- [2-（3-氨基丁酰胺基）-4 -乙氧基苯基]吡啶（24i）显示有效的抗心律不齐活性。他们具有美西律（III）效力的大约两倍。从该系列中选择化合物24i作为进一步开发的候选化合物；它被发现具有IB类电生理特性，并显示出心肌中钠通道的慢速依赖于速率的阻滞（RDB）。
• [EN] ERAP1 MODULATORS<br/>[FR] MODULATEURS ERAP1
  申请人：GREY WOLF THERAPEUTICS LTD

  公开号：WO2021094763A1

  公开（公告）日：2021-05-20

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, (I) wherein: Z is a group of formula: (II) wherein P and Q are each independently CR12R13; or one of P and Q is NR14 and the other is CR12R13; the group X-Y is -NHSO2- or -SO2NH-; R1 is H, CN or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, heteroaryl, SO2NR16R17, CONR10R11 and alkyl, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H or halo; and R10, R11, R12, R13, R14, R16 and R17 are each independently H or alkyl; R15 is selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; and m and n are each independently 0, 1, 2 or 3. Further aspects of the invention relate to such compounds for use in the field of immune-oncology and related applications.

  本发明涉及一种具有以下结构的化合物（I）或其药用可接受的盐或水合物，其中：Z是以下结构的基团（II），其中P和Q分别独立地为CR12R13；或者P和Q中的一个为NR14，另一个为CR12R13；基团X-Y为-NHSO2-或-SO2NH-；R1为H，CN或烷基；R2选自COOH和四氮唑基团；R3选自H、Cl和烷基；R4选自H和卤素；R5选自H、烷基、卤代烷基、SO2-烷基、Cl、烷氧基、OH、CN、羟基烷基、烷基硫醚、杂环芳基、环烷基、杂环烷基和卤代烷氧基；R6为H；R7选自H、CN、卤代烷基、卤素、SO2-烷基、杂环芳基、SO2NR16R17、CONR10R11和烷基，其中所述的杂环芳基可以选择地由一种或多种取代基选自烷基、卤素、烷氧基、CN、卤代烷基和羟基取代；R8选自H、烷基、卤代烷基和卤素；R9为H或卤素；R10、R11、R12、R13、R14、R16和R17各自独立地为H或烷基；R15选自烷基、卤素、烷氧基、CN、卤代烷基和羟基；m和n各自独立地为0、1、2或3。该发明的进一步方面涉及这些化合物在免疫肿瘤学领域及相关应用中的使用。
• Macrocylic Inhibitors of Hepatitis C Virus
  申请人：Simmen Kenneth Alan

  公开号：US20090105302A1

  公开（公告）日：2009-04-23

  Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R 1 is —OR 6 , —NH—SO 2 R 7 ; R 2 is hydrogen, and where X is C or CH, R 2 may also be C 1-6 alkyl; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, or C 3-7 cycloalkyl; n is 3, 4, 5, or 6; R 4 and R 5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkoxy-carbonyl, amino, azido, mercapto, C 1-6 alkylthio, polyhaloC 1-6 alkyl, aryl or Het; W is aryl or Het; R 6 is hydrogen; aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; R 7 is aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1-4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1-3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

  HCV复制抑制剂的公式(I)及其N-氧化物、盐或立体异构体，其中每个虚线（由- - - - -表示）表示可选的双键；X为N、CH，其中X带有双键时为C；R1为—OR6、—NH—SO2R7；R2为氢，当X为C或CH时，R2也可以是C1-6烷基；R3为氢、C1-6烷基、C1-6烷氧基C1-6烷基或C3-7环烷基；n为3、4、5或6；R4和R5相互独立，为氢、卤素、羟基、硝基、氰基、羧基、C1-6烷基、C1-6烷氧基、C1-6烷氧基C1-6烷基、C1-6烷基羰基、C1-6烷氧羰基、氨基、偶氮基、巯基、C1-6烷基硫基、多卤素C1-6烷基、芳基或杂环基；W为芳基或杂环基；R6为氢、芳基、杂环基、C3-7环烷基，可选地被C1-6烷基取代；或C1-6烷基，可选地被C3-7环烷基、芳基或杂环基取代；R7为芳基、杂环基、C3-7环烷基，可选地被C1-6烷基取代；或C1-6烷基，可选地被C3-7环烷基、芳基或杂环基取代；芳基为苯基或萘基，每个可选地取代1-3个取代基；杂环基为含有1-4个杂原子的5或6元饱和、部分不饱和或完全不饱和的杂环，每个独立选择自N、O或S，并可选地取代1-3个取代基；包含化合物(I)的制药组合物和制备化合物(I)的方法。还提供了公式(I)的HCV抑制剂与利托那韦的生物利用度组合。
• Trk-INHIBITING COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20150111865A1

  公开（公告）日：2015-04-23

  An object of the present invention is to provide a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I): (wherein all symbols represent the same meanings as described in the specification), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.

  本发明的目的是提供一种药物，其含有具有Trk抑制活性的化合物作为活性成分，用于预防和/或治疗疼痛、瘙痒、下尿路功能障碍、哮喘、过敏性鼻炎、炎症性肠病或查加斯病等疾病。一种由通式（I）表示的化合物（其中所有符号的含义如说明书中所述），其盐、N-氧化物、溶剂化合物或前药是有用的药物成分，具有Trk抑制活性，用于预防和/或治疗疼痛、瘙痒、下尿路功能障碍、哮喘、过敏性鼻炎、炎症性肠病或查加斯病等疾病。